Literature DB >> 16957386

Transgene-like animal models using intronic microRNAs.

Shi-Lung Lin1, Shin-Ju E Chang, Shao-Yao Ying.   

Abstract

Transgenic animal models are valuable tools for testing gene functions and drug mechanisms in vivo. They are also the best similitude of a human body for etiological and pathological research of diseases. All pharmaceutically developed drugs must be proven safe and effective in animals before approval by the Food and Drug Administration to be used in clinical trials. To this end, the transgenic animal models of human diseases serve as a front line for drug evaluation. However, there is currently no transgenic animal model for microRNA (miRNA) research. miRNAs, small single-stranded regulatory RNAs capable of silencing intracellular gene transcripts that contain either complete or partial complementarity to the miRNAs, are useful for the design and development of new therapies against cancer polymorphism and viral mutation. Recently, varieties of natural miRNAs have been found to be derived from hairpin-like RNA precursors in almost all eukaryotes, including yeast (Schizosaccharomyces pombe), plant (Arabidopsis), nematode (Caenorhabditis elegans), fly (Drosophila melanogaster), fish, mouse, and human, involving intracellular defense against viral infections and regulation of certain gene expressions during development. To facilitate the miRNA research in vivo, we have developed a state-of-the-art transgenic strategy for silencing specific genes in zebrafish, chicken, and mouse, using intronic miRNAs. By insertion of a hairpin-like pre-miRNA structure into the intron region of a gene, we have found that mature miRNAs were successfully transcribed by RNA polymerase (Pol)-II, coexpressed with the encoding gene transcript, and excised out of the encoding gene transcript by natural RNA splicing and processing mechanisms. In conjunction with retroviral transfection systems, the hairpin-like pre-miRNA construct was further inserted into the intron of a cellular gene for tissue-specific expression regulated by the gene promoter. Because the retroviral vectors were randomly integrated into the genome of its host cell, the most effective transgenic animal can be selected and propagated to be a stable transgenic line for future research. Here, we have shown for the first time that transgene-like animal models were generated using the intronic miRNA-expressing system described previously, which has been proven to be useful for both miRNA research and in vivo evaluation of miRNA-associated target genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957386     DOI: 10.1385/1-59745-123-1:321

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

1.  Loss of mir-146a function in hormone-refractory prostate cancer.

Authors:  Shi-Lung Lin; Angela Chiang; Donald Chang; Shao-Yao Ying
Journal:  RNA       Date:  2008-01-03       Impact factor: 4.942

2.  Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state.

Authors:  Shi-Lung Lin; Donald C Chang; Samantha Chang-Lin; Chun-Hung Lin; David T S Wu; David T Chen; Shao-Yao Ying
Journal:  RNA       Date:  2008-08-28       Impact factor: 4.942

3.  Advances in microRNA-mediated reprogramming technology.

Authors:  Chih-Hao Kuo; Shao-Yao Ying
Journal:  Stem Cells Int       Date:  2012-03-28       Impact factor: 5.443

4.  Mir-434-5p mediates skin whitening and lightening.

Authors:  David Ts Wu; Jack S Chen; Donald C Chang; Shi-Lung Lin
Journal:  Clin Cosmet Investig Dermatol       Date:  2008-10-07

Review 5.  Mechanism of repeat-associated microRNAs in fragile X syndrome.

Authors:  Karen Kelley; Shin-Ju E Chang; Shi-Lung Lin
Journal:  Neural Plast       Date:  2012-06-20       Impact factor: 3.599

6.  MicroRNA let-7f-5p regulates PI3K/AKT/COX2 signaling pathway in bacteria-induced pulmonary fibrosis via targeting of PIK3CA in forest musk deer.

Authors:  Wei Zhao; Jianguo Cheng; Yan Luo; Wenlong Fu; Lei Zhou; Xiang Wang; Yin Wang; Zexiao Yang; Xueping Yao; Meishen Ren; Zhijun Zhong; Xi Wu; Ziwei Ren; Yimeng Li
Journal:  PeerJ       Date:  2022-10-05       Impact factor: 3.061

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.